Publication Date
1-1-2022
Journal
Frontiers in Oncology
DOI
10.3389/fonc.2022.928390
PMID
36081549
PMCID
PMC9445222
PubMedCentral® Posted Date
8-23-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
checkpoint inhibitor therapy, glucocorticoids, immunosuppressants, cancer, immunotherapy
Abstract
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs). Moderate to severe irAEs are typically treated with glucocorticoids, sometimes with the addition of immunosuppressants as steroid-sparing therapy. However, it is unclear how glucocorticoids and immunosuppressants may impact cancer survival and the efficacy of immune checkpoint therapy on cancer. In this narrative review, we discuss the effects of glucocorticoids and immunosuppressants including methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, tumor-necrosis factor (TNF)-inhibitors, interleukin-6 inhibitors, interleukin-1 inhibitors, abatacept, rituximab, and Janus kinase inhibitors (JAKi) on cancer-specific outcomes in the setting of immune checkpoint inhibitor use.
Included in
Allergy and Immunology Commons, Immune System Diseases Commons, Immunotherapy Commons, Medical Immunology Commons